ZB-06 is under clinical development by ZabBio and currently in Phase I for Female Contraception. According to GlobalData, Phase I drugs for Female Contraception have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZB-06’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZB-06 is under development for the treatment of female contraception. The therapeutic candidate is delivering to the vagina via intravaginal ring (IVR). It is a multimeric construct comprised of a total of six Fab domains linked to the IgG molecule.
ZabBio is a pharmaceutical company developing monoclonal antibody-based products that address unmet needs in infectious diseases and reproductive health. It is headquartered in San Diego, California, the US.
For a complete picture of ZB-06’s drug-specific PTSR and LoA scores, buy the report here.